Zentalis Pharmaceuticals Llc (US:ZNTL) — Company Overview, News & Financial Data

Zentalis Pharmaceuticals Llc logo
ZNTLZentalis Pharmaceuticals Llc
Trade ZNTL now
Zentalis Pharmaceuticals Llc primary media

About Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is a biopharmaceutical company focused on discovering and developing small molecule therapeutics aimed at addressing various forms of cancer. Leveraging its proprietary technology platforms, Zentalis is working on a pipeline of oncology compounds with the potential to improve the lives of patients by targeting the molecular and genetic drivers of cancer. The company's objective is to push the boundaries of what is possible in cancer treatment by creating medicines that offer new hope and better outcomes. With a focus on rigorous science and a commitment to innovation, Zentalis Pharmaceuticals strives to bring forward novel therapies that address unmet medical needs in the oncology space.

What is ZNTL known for?

Snapshot

Public US
Ownership
2014
Year founded
173
Employees
New York, United States
Head office
Loading Map...

Operations

All Locations
New York City, US

Products and/or services of Zentalis Pharmaceuticals Llc

  • Development of ZN-c3, a Wee1 inhibitor for treating solid tumors.
  • Investigation of ZN-d5, a BCL-2 inhibitor aimed at blood cancers.
  • Research on ZN-c5, an oral SERD for estrogen receptor-positive breast cancer.
  • Exploration of combination therapies using their proprietary compounds to enhance cancer treatment efficacy.
  • Advancing ZN-e4, a candidate for treating non-small cell lung cancer.
  • Collaboration on biomarker-driven projects to personalize and improve cancer treatment outcomes.

Zentalis Pharmaceuticals Llc executive team

  • Ms. Julie M. Eastland M.B.A.CEO, President & Director
  • Mr. Vincent A. VultaggioSVP of Finance & Principal Accounting Officer
  • Mr. James B. Bucher J.D.Chief Legal Officer & Corporate Secretary
  • Ms. Wendy ChangChief People Officer
  • Mr. Robert J. DiVasto P.E.Senior Vice President of Technical Operations
  • Dr. Ingmar Bruns M.D., Ph.D.Chief Medical Officer
  • Mr. Haibo WangChief Business Officer
  • Mr. Rajesh IsraniSenior VP of Regulatory Affairs & Medical Writing
  • Mr. Henry GuSenior VP & Head of Intellectual Property

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.